Dollar Amounts
USD (Millions)
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Assets | $2,390 | $2,612 | $2,534 | $2,990 | $3,004 |
| Liabilities | $1,546 | $1,840 | $1,961 | $2,603 | $2,415 |
| Equity | $843 | $772 | $573 | $387 | $588 |
Balance sheet data in USD (millions)
Doing some research...
Edwyn
Over the past five years, Ionis Pharmaceuticals, Inc. has shown a mixed financial performance. Total assets have been steadily increasing, reaching a peak in 2024 at $3.004 billion. This growth suggests that the company has been investing in its operations, potentially through acquisitions, research and development, or other strategic initiatives. On the other hand, total liabilities have also been on the rise, with a significant spike in 2023 to $2.603 billion. This increase in liabilities could indicate higher debt levels or obligations taken on to fund expansion efforts. Stockholders' equity has fluctuated notably, dropping from $843.347 million in 2020 to $386.686 million in 2023 before rebounding to $588.351 million in 2024. The decrease in equity in 2023 may raise concerns about the company's financial leverage and ability to weather economic downturns. It would be essential for Ionis Pharmaceuticals to closely monitor its debt levels and ensure that its equity position remains strong to support future growth and innovation in the competitive pharmaceutical industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.